U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H19ClN2
Molecular Weight 310.8212
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESLORATADINE

SMILES

c1cc2CCc3cc(ccc3C(=C4CCNCC4)c2nc1)Cl

InChI

InChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

1.00889277E12
Palliative
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

1.00889277E12
Palliative
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

1.00889277E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4 ng/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
56.9 ng × h/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
27 h
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
84.5%
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources: Page: p. 25
unhealthy, 2-11 years
n = 48
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Population Size: 48
Sources: Page: p. 25
Disc. AE: Somnolence, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Somnolence (1 patient)
Abdominal pain (1 patient)
Sources: Page: p. 25
45 mg 1 times / day multiple, oral
Highest studied dose
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M+F
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 1 patient
Disc. AE
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources: Page: p. 25
unhealthy, 2-11 years
n = 48
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Population Size: 48
Sources: Page: p. 25
Somnolence 1 patient
Disc. AE
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources: Page: p. 25
unhealthy, 2-11 years
n = 48
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Population Size: 48
Sources: Page: p. 25
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
not significant [IC50 43 uM]
strong [Ki 1.3 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
likely
likely
no (pharmacogenomic study)
Comment: pharmacogenotype 2C19 does not correlate with systemic exposure
Page: 19.0
likely
no (pharmacogenomic study)
Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation
Page: 10.0
likely
weak (co-administration study)
Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively.
Page: 10.0
yes
yes
weak (co-administration study)
Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively.
Tox targets
PubMed

PubMed

TitleDatePubMed
[The effect of second generation histamine antagonists on the heart].
2001
Desloratadine.
2001
The pharmacologic profile of desloratadine: a review.
2001
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction.
2001
Desloratadine in the treatment of chronic idiopathic urticaria.
2001
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma.
2001
Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis.
2001
Desloratadine: A new, nonsedating, oral antihistamine.
2001 Apr
Evaluation of a four-channel multiplexed electrospray triple quadrupole mass spectrometer for the simultaneous validation of LC/MS/MS methods in four different preclinical matrixes.
2001 Apr 15
Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma.
2001 Apr 20
[A new antihistamine. Inhibiting inflammation in rhinorrhea and nasal congestion].
2001 Apr 5
Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells.
2001 Aug
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein.
2001 Aug
Applications of new liquid chromatography-tandem mass spectrometry technologies for drug development support.
2001 Aug 10
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
2001 Jan
[Urticaria. Finally undisturbed sleep].
2001 Jul 26
Chronic idiopathic urticaria treatment.
2001 Jul-Aug
Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug.
2001 Mar
Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
2001 Mar
In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.
2001 Sep
Mediator antagonists in the treatment of allergic disease.
2001 Sep-Oct
Second-generation antihistamines in asthma therapy: is there a protective effect?
2002
Advances in allergy management.
2002
Therapeutic points of intervention and clinical implications: role of desloratadine.
2002
Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.
2002
A pharmacokinetic profile of desloratadine in healthy adults, including elderly.
2002
Desloratadine demonstrates dose proportionality in healthy adults after single doses.
2002
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].
2002 Aug 5
Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor.
2002 Aug 9
The new antihistamines--desloratadine and levocetirizine: a review.
2002 Dec
Chronic urticaria: a role for newer immunomodulatory drugs?
2003
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.
2003 Aug
Studies on performance and sleepiness with the H1-antihistamine, desloratadine.
2003 Aug
Gateways to clinical trials.
2003 Dec
Interactions of olopatadine and selected antihistamines with model and natural membranes.
2003 Dec
Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
2003 Jul
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.
2003 Jul
Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma.
2003 Jul 25
[Safety of new antihistamines].
2003 Jun
[Clinical aspects of anti-inflammatory action of antihistamines].
2003 Jun
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.
2003 Jun
Gateways to clinical trials. March 2003.
2003 Mar
Double-stranded RNA viruses in a mycocinogenic strain of Cystofilobasidium infirmominiatum.
2003 Mar
Decongestant effects of antihistamines: a class effect?
2003 Mar
Desloratadine for allergic rhinitis.
2003 Nov 15
Loratadine, desloratadine and pregnancy: don't use, risk of hypospadias.
2003 Oct
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects].
2003 Oct 30
Inhibition of cold urticaria by desloratadine.
2004 Jan
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research.
2004 Jan
Gateways to clinical trials.
2004 Jan-Feb
Patents

Sample Use Guides

Adults and Adolescents 12 Years of Age and Over: take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.
Route of Administration: Oral
In Vitro Use Guide
Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.
Name Type Language
DESLORATADINE
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
LORATADINE RELATED COMPOUND A [USP]
Common Name English
8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2-BPYRIDINE
Common Name English
DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE RATIOPHARM
Brand Name English
8-CHLORO-6,11-DIHYDRO-11(4-PIPERIDYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2-B) PYRIDINE
Common Name English
DENOSIN
Brand Name English
DESLORATADINE [INN]
Common Name English
DASSELTA
Brand Name English
NSC-759824
Code English
DESLORATADINE [MART.]
Common Name English
RUPATADINE FUMARATE IMPURITY B [EP]
Common Name English
NEOCLARITYN
Brand Name English
DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE [MI]
Common Name English
DESLORATADINE [VANDF]
Common Name English
DESLORATADINE [USP-RS]
Common Name English
LORATADINE SPECIFIED IMPURITY D [EP]
Common Name English
DESLORATADINE [USP MONOGRAPH]
Common Name English
CLARINEX
Brand Name English
DESCARBOETHOXYLORATADINE
Common Name English
DESLORATADINE ACTAVIS
Brand Name English
DESLORATADINE TEVA (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE [ORANGE BOOK]
Common Name English
8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE
Common Name English
CLARINEX-D COMPONENT DESLORATADINE
Common Name English
DESLORATADINE [WHO-DD]
Common Name English
OPULIS
Brand Name English
SCH-34117
Code English
AZOMYR
Brand Name English
ALLEX
Brand Name English
DESLORATADINE TEVA
Brand Name English
AERIUS
Brand Name English
DESLORATADINE [JAN]
Common Name English
LORATADINE RELATED COMPOUND A [USP-RS]
Common Name English
DESLORATADINE [EMA EPAR]
Common Name English
DESLORATADINE [EP MONOGRAPH]
Common Name English
DESLORATADINE [USAN]
Common Name English
DESLORATADINE COMPONENT OF CLARINEX-D
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS DESLORATADINE TEVA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
LIVERTOX 284
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
WHO-VATC QR06AX27
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS OPULIS (WITHDRAWN: RHINITIS, URTICARIA)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
NCI_THESAURUS C29578
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
NDF-RT N0000175587
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS ALLEX(WITHDRAWN: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS DASSELTA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS AZOMYR (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
WHO-ATC R06AX27
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS AERINAZE (AUTHORIZED: RHINITIS)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS AERIUS(AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS NEOCLARITYN (AUTHORIZED: RHINITIS, URTICARIA)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
NDF-RT N0000000190
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
Code System Code Type Description
USP_CATALOG
1370280
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY USP-RS
USP_CATALOG
1173042
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY USP-RS
ChEMBL
CHEMBL1172
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
DRUG BANK
DB00967
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
MESH
C121345
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
INN
7817
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
RXCUI
275635
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY RxNorm
EPA CompTox
100643-71-8
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
LACTMED
Desloratadine
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
NCI_THESAURUS
C47474
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
PUBCHEM
124087
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
DRUG CENTRAL
814
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
FDA UNII
FVF865388R
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
WIKIPEDIA
Desloratadine
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
IUPHAR
7157
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
MERCK INDEX
M4193
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY Merck Index
EVMPD
SUB01596MIG
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
CAS
100643-71-8
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY